“As the first orally administered on-demand therapy for HAE attacks, EKTERLY provides patients and physicians with an important and welcome advance in HAE treatment options,” said Anthony J. Castaldo, ...

First trial participant treated with PTM-101, an investigational thin film formulation of paclitaxel placed directly over the tumor for continuous localized ...

Research published in Science Advances indicates that CVXGA is a promising intranasal vaccine candidate that is safe, immunogenic and potentially effective ...

GENEVA, Switzerland I July 07, 2025 I Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced its ...

PARIS, France I July 07, 2025 I PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with ...

TOKYO, Japan I July 7, 2025 I Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519, hereafter “Chugai”), and Gero PTE. LTD. (hereafter “Gero”), a Singapore-based ...

VIENNA, Austria / BERLIN, Germany I July 7, 2025 I HeartBeat.bio AG and biotx.ai GmbH today announced astrategic partnership to identify and validate ...

SHANGHAI, China I July 4, 2025 I Everest Medicines (HKEX: 1952.HK), a biopharmaceutical company focused on the discovery, clinical development, manufacturing ...

Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the ...

CINCINNATI, OH, USA I July 4, 2025 I During the COVID-19 pandemic, scientists learned that the critical path to infection started with the SARS-CoV-2 virus ...

BOSTON, MA, USA I July 4, 2025 I HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule ...

GUANGZHOU, China I July 2, 2025 I Bio-Thera Solutions, Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today announced ...